Home LiteratureArticle Details

PMID: 12595488 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.

Infection and immunity ·Vol. 71 ·No. 3 ·2003-03-00 ·Pages 1608-10

Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S, Giannasca PJ, Monath TP, Kelly CP

Abstract

There is a strong association between serum antibody responses to toxin A and protection against Clostridium difficile diarrhea. A parenteral C. difficile toxoid vaccine induced very-high-level responses to anti-toxin A immunoglobulin G (IgG) in the sera of healthy volunteers. After vaccination, the concentrations of anti-toxin A IgG in the sera of all 30 recipients exceeded the concentrations that were associated with protection in previous clinical studies. Furthermore, the median concentration of serum anti-toxin A IgG in the test group was 50-fold higher than the previous threshold. These findings support the feasibility of using a vaccine to protect high-risk individuals against C. difficile-associated diarrhea and colitis.

MeSH Terms

Adult Antibodies, Bacterial/blood Bacterial Toxins/immunology Bacterial Vaccines/immunology Clostridioides difficile/immunology Diarrhea/prevention & control Enterotoxins/immunology Humans Immunoglobulin G/blood Toxoids/immunology Vaccination

Chemicals

Antibodies, Bacterial Bacterial Toxins Bacterial Vaccines Enterotoxins Immunoglobulin G Toxoids tcdA protein, Clostridium difficile

Authors & Affiliations

9 authors, click to expand affiliations / ORCID

Aboudola Samer

Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Kotloff Karen L

Kyne Lorraine

Warny Michel

Kelly Eoin C

Sougioultzis Stavros

Giannasca Paul J

Monath Thomas P

Kelly Ciarán P

References (21)

21 references, click to expand

Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay.
Ann Intern Med. 2001 Sep 18;135(6):434-8 PMID: 11560456
Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile.
J Clin Microbiol. 2000 Apr;38(4):1696-7 PMID: 10747174
Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.
Infect Immun. 1994 Feb;62(2):384-9 PMID: 8300199
Clostridium difficile.
Gastroenterol Clin North Am. 2001 Sep;30(3):753-77, ix-x PMID: 11586556
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
N Engl J Med. 2000 Feb 10;342(6):390-7 PMID: 10666429
Prospects for a vaccine for Clostridium difficile.
BioDrugs. 1998 Sep;10(3):173-81 PMID: 18020593
Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain.
Eur J Clin Microbiol Infect Dis. 2001 Aug;20(8):528-34 PMID: 11681431
Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.
Gut. 1997 Sep;41(3):366-70 PMID: 9378393
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.
Lancet. 2001 Jan 20;357(9251):189-93 PMID: 11213096
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.
Infect Immun. 2001 Feb;69(2):988-95 PMID: 11159994
Role of antibody response in outcome of antibiotic-associated diarrhoea.
Lancet. 2001 Jan 20;357(9251):158-9 PMID: 11213086
Immune response to Clostridium difficile infection.
Eur J Gastroenterol Hepatol. 1996 Nov;8(11):1048-53 PMID: 8944364
Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection.
Infect Immun. 1998 May;66(5):2018-25 PMID: 9573084
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro.
J Clin Invest. 1995 May;95(5):2004-11 PMID: 7738167
Epidemiology of nosocomial clostridium difficile diarrhoea.
J Hosp Infect. 1999 Dec;43 Suppl:S183-90 PMID: 10658778
Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease.
Infect Immun. 2000 Oct;68(10):5480-7 PMID: 10992443
Nosocomial acquisition of Clostridium difficile infection.
N Engl J Med. 1989 Jan 26;320(4):204-10 PMID: 2911306
Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.
J Infect Dis. 1992 Dec;166(6):1287-94 PMID: 1431247
Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea.
Infection. 1985 May-Jun;13(3):97-101 PMID: 4030111
Clinical practice. Antibiotic-associated diarrhea.
N Engl J Med. 2002 Jan 31;346(5):334-9 PMID: 11821511
Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.
J Pediatr. 1991 Apr;118(4 Pt 1):633-7 PMID: 1901084

Article Info

Journal

Infection and immunity

Abbr.

Infect Immun

ISSN

0019-9567

DOI

10.1128/IAI.71.3.1608-1610.2003

Published

2003-03-00

Pages

1608-10

Language

English

Region

United States

NLM ID

0246127

PMCID

PMC148861

Subset

Grants

Intramural NIH HHS · Z01 AG000971 · United States

NCRR NIH HHS · M01 RR001032 · United States

NIA NIH HHS · K23 AG000971 · United States

NCRR NIH HHS · RR-01032 · United States

NIAID NIH HHS · AI-45251 · United States

External Links

PubMed source DOI: 10.1128/IAI.71.3.1608-1610.2003 PMC Full Text View journal details

Analysis Services

Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.

Contact

WeChat Official Account